JPH06312937A - Production of substance having curing effect for wound - Google Patents
Production of substance having curing effect for woundInfo
- Publication number
- JPH06312937A JPH06312937A JP5104725A JP10472593A JPH06312937A JP H06312937 A JPH06312937 A JP H06312937A JP 5104725 A JP5104725 A JP 5104725A JP 10472593 A JP10472593 A JP 10472593A JP H06312937 A JPH06312937 A JP H06312937A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- wound
- producing
- mycelium
- fruiting body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、マイタケから抽出する
創傷部の治療効果を有する物質の製造方法に関するもの
である。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for producing a substance having a therapeutic effect on a wound extracted from Maitake mushrooms.
【０００２】[0002]
【従来の技術及び発明が解決しようとする課題】創傷部
の治療には、その組織の結合及び癒着が早く行われる
こと、或いは血管から該組織に栄養及び酸素の供給が
十分に与えられることが必要となる。本発明者は種々検
討した結果、マイタケからの抽出成分が、前記，を
促すという事実を確認し、本発明を完成させた。2. Description of the Related Art In the treatment of a wound, the tissue is quickly joined and adhered, or the blood vessel is sufficiently supplied with nutrients and oxygen. Will be needed. As a result of various studies, the present inventor has confirmed the fact that the extracted component from Maitake mushroom promotes the above-mentioned, and completed the present invention.
【０００３】[0003]
【課題を解決するための手段】添付図面を参照して本発
明の要旨を説明する。The gist of the present invention will be described with reference to the accompanying drawings.
【０００４】創傷部の治療効果を有する物質の製造方法
であって、マイタケの菌糸体若しくは子実体から抽出す
ることを特徴とする創傷部の治療効果を有する物質の製
造方法に係るものである。The present invention relates to a method for producing a substance having a therapeutic effect on a wound, which is characterized by being extracted from a mycelium or fruiting body of Maitake mushroom.
【０００５】マイタケの菌糸体若しくは子実体またはこ
れらを熱水処理して得られる可溶性画分にアルコールを
添加して得られる不溶性物質に、デンプンなどの支持体
を混合して生成することを特徴とする創傷部の治療効果
を有する物質の製造方法に係るものである。A mycelium or fruiting body of Maitake mushroom or an insoluble substance obtained by adding alcohol to a soluble fraction obtained by treating these with hot water is mixed with a support such as starch. The present invention relates to a method for producing a substance having a therapeutic effect on a wound site.
【０００６】請求項１，２記載の創傷部の治療効果を有
する物質の製造方法において、マイタケの菌糸体若しく
は子実体として、粉末のマイタケの菌糸体若しくは子実
体を採用したことを特徴とする創傷部の治療効果を有す
る物質の製造方法に係るものである。[0006] In the method for producing a substance having a therapeutic effect on a wound part according to any one of claims 1 and 2, powdered mycelium or fruiting body of Maitake mushroom is used as the mycelium or fruiting body of Maitake mushroom. The present invention relates to a method for producing a substance having a therapeutic effect on some parts.
【０００７】[0007]
【実施例】マイタケ（白マイタケ、チョレイマイタケな
どを含む。）粉末５００ｇ（栄養菌糸体および子実体の
いずれでも可）、またこれから熱水１ｌで抽出して得た
可溶性画分７０〜８０ｇに、エチルアルコールを３０〜
８５％濃度（重量濃度）になるよう添加して得られた不
溶性物質１５〜２０ｇに、デンプン，乳糖などを支持体
として２００mg混合し、各々を打錠した錠剤及び、これ
らをカプセルにつめたカプセル剤を作製した。[Examples] Powdered maitake mushrooms (including white maitake mushrooms, chorei maitake mushrooms, etc.) powder 500 g (both vegetative mycelium and fruiting body are acceptable), and a soluble fraction 70-80 g obtained by extraction with 1 l of hot water , Ethyl alcohol 30 ~
200 mg of starch, lactose, etc., as a support, was mixed with 15 to 20 g of the insoluble substance obtained by adding so as to have a concentration of 85% (weight concentration), and tablets were formed into tablets and capsules containing these capsules. An agent was prepared.
【０００８】尚、抽出に際してアルコールを使用するこ
とで該アルコールに溶出する物質を抽出している。即
ち、抽出物質は脂質が主体となる物質である為、抽出に
際してアルコールを使用している。It should be noted that a substance that is eluted in the alcohol is extracted by using alcohol in the extraction. That is, since the extracted substance is mainly a lipid, alcohol is used for extraction.
【０００９】これを、あらかじめ剃毛し１ｃｍの長さに
切傷を皮膚に手術的に作製したマウスに１日あたり１〜
２錠または同量のカプセル剤を経口的に投与した。[0009] This was applied to a mouse that had been shaved in advance and surgically made a cut on the skin to a length of 1 cm to 1 to 1 per day.
Two tablets or the same amount of capsules were orally administered.
【００１０】投与後４日、８日及び１４日後にマウスの
切部の癒着程度を調べるため一端を固定後切傷の一端を
引張り、開傷するのに要する重量を測定した。Four days, eight days and fourteen days after the administration, one end of the incision was pulled after fixing one end and the weight required to open the wound was measured in order to examine the adhesion degree of the incision of the mouse.
【００１１】表１にその結果を示す。Table 1 shows the results.
【００１２】[0012]
【表１】 [Table 1]
【００１３】本物質の経口投与により開傷に要する重量
は無処理群に比べ約２倍以上を必要とする結果が得られ
た。この結果は創傷部の癒着（創傷部の結合組織を介し
ての閉傷効果）が本物質によって促進されたことを示
す。The result of oral administration of this substance was that the weight required for wounding was about twice or more that of the untreated group. This result indicates that the adhesion of the wound site (closure effect through the connective tissue of the wound site) was promoted by this substance.
【００１４】次に、閉傷した部分の皮膚の厚さを検討し
表２の結果を得た。Next, the thickness of the skin in the closed area was examined and the results shown in Table 2 were obtained.
【００１５】この表は、癒着によって閉傷した部分が本
物質によって肥厚し創傷部の閉傷が促された事実を示す
ものである。This table shows the fact that the wounded portion due to adhesion was thickened by this substance and the wounded portion was closed.
【００１６】[0016]
【表２】 [Table 2]
【００１７】尚、表１，２はマイタケ粉末のみからなる
物質の投与による結果であるが、前記各抽出物質を混入
させた錠剤やカプセル錠でも同様な結果が確認されてい
る。更に、支持体を用いず各抽出物質を皮下投与した場
合には、その効果はより強く発現されることも見出し
た。Tables 1 and 2 show the results obtained by administration of a substance consisting of powdered maitake mushrooms, but similar results have been confirmed for tablets and capsules containing the aforementioned extracted substances. Furthermore, it was also found that when each extract substance was subcutaneously administered without using a support, the effect was more strongly expressed.
【００１８】以上のことより、マイタケ粉末及びその前
記各抽出物質は、経口投与するか、或いは創傷部に皮下
注射するか、或いはこれらを創傷部に塗布することによ
って創傷部を治療する効果を有することが明らかであ
る。From the above, the maitake powder and each extract thereof are effective in treating the wound by oral administration, subcutaneous injection into the wound, or application of these to the wound. It is clear.
【００１９】[0019]
【発明の効果】本発明は上述のようにしたから、秀れた
創傷部の治療効果を有する物質の製造方法となる。As described above, the present invention provides a method for producing a substance having an excellent therapeutic effect on a wound.
Claims (3)
法であって、マイタケの菌糸体若しくは子実体から抽出
することを特徴とする創傷部の治療効果を有する物質の
製造方法。1. A method for producing a substance having a therapeutic effect on a wound, which comprises extracting from a mycelium or fruiting body of Maitake mushroom.
これらを熱水処理して得られる可溶性画分にアルコール
を添加して得られる不溶性物質に、デンプンなどの支持
体を混合して生成することを特徴とする創傷部の治療効
果を有する物質の製造方法。2. A mycelium or fruiting body of Maitake mushroom or an insoluble substance obtained by adding alcohol to a soluble fraction obtained by treating these with hot water is mixed with a support such as starch. A method for producing a substance having a characteristic wound healing effect.
有する物質の製造方法において、マイタケの菌糸体若し
くは子実体として、粉末のマイタケの菌糸体若しくは子
実体を採用したことを特徴とする創傷部の治療効果を有
する物質の製造方法。3. The method for producing a substance having a therapeutic effect on a wound part according to claim 1, wherein powdered mycelium or fruiting body of Maitake mushroom is adopted as the mycelium or fruiting body of Maitake mushroom. A method for producing a substance having a therapeutic effect on a wound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5104725A JP2698956B2 (en) | 1993-04-30 | 1993-04-30 | Method for producing wound treatment agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5104725A JP2698956B2 (en) | 1993-04-30 | 1993-04-30 | Method for producing wound treatment agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06312937A true JPH06312937A (en) | 1994-11-08 |
| JP2698956B2 JP2698956B2 (en) | 1998-01-19 |
Family
ID=14388478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5104725A Expired - Lifetime JP2698956B2 (en) | 1993-04-30 | 1993-04-30 | Method for producing wound treatment agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2698956B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1170015A1 (en) * | 2000-07-06 | 2002-01-09 | Laboratoires Serobiologiques(Societe Anonyme) | Use of extracts of the fungus Grifola frondosa |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52117493A (en) * | 1976-03-26 | 1977-10-01 | Kisaku Mori | Extraction of medically effective substance of mushroom |
| JPS5893702A (en) * | 1981-12-01 | 1983-06-03 | Sankyo Co Ltd | Beta-1,3-glucan and its preparation |
| JPS638336A (en) * | 1986-06-27 | 1988-01-14 | Iwase Kosufua Kk | External preparation for skin |
| JPH0449244A (en) * | 1990-06-15 | 1992-02-18 | Chiba Seifun Kk | Antidiabetic agent and antidiabetic agent for animal |
-
1993
- 1993-04-30 JP JP5104725A patent/JP2698956B2/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52117493A (en) * | 1976-03-26 | 1977-10-01 | Kisaku Mori | Extraction of medically effective substance of mushroom |
| JPS5893702A (en) * | 1981-12-01 | 1983-06-03 | Sankyo Co Ltd | Beta-1,3-glucan and its preparation |
| JPS638336A (en) * | 1986-06-27 | 1988-01-14 | Iwase Kosufua Kk | External preparation for skin |
| JPH0449244A (en) * | 1990-06-15 | 1992-02-18 | Chiba Seifun Kk | Antidiabetic agent and antidiabetic agent for animal |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1170015A1 (en) * | 2000-07-06 | 2002-01-09 | Laboratoires Serobiologiques(Societe Anonyme) | Use of extracts of the fungus Grifola frondosa |
| WO2002002129A1 (en) * | 2000-07-06 | 2002-01-10 | Cognis France S.A. | Use of grifola frondosa fungus extracts |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2698956B2 (en) | 1998-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Way et al. | Inhibition of gastric acid secretion in vitro by prostaglandin E1 | |
| CA1234754A (en) | Agent and product for the diagnosis and treatment of tumors and for the treatment of weaknesses of the cellular and humoral immune defense | |
| EP1095656A3 (en) | Pharmaceutical preparation comprising Galanthamine as cholinesterase inhibitor | |
| WO2003053362A3 (en) | Systems and methods for treating patients with collagen-rich material extracted from adipose tissue | |
| HU227944B1 (en) | Vaccines containing a saponin and a sterol | |
| EP2335727A3 (en) | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody | |
| ATE142483T1 (en) | METHOD FOR TREATING INFECTED TISSUES | |
| WO2001052921A3 (en) | Valve arrangement | |
| JP2005519985A5 (en) | ||
| WO2000040269A3 (en) | Pharmaceutical compositions for treatment of diseased tissues | |
| US6007813A (en) | Method and composition for treating ulcers and secretion of gastric acid | |
| Honn et al. | Inhibition of DNA synthesis in Harding-Passey melanoma cells by prostaglandins A1 and A2: comparison with chemotherapeutic agents | |
| CA2282234A1 (en) | Antitumor activity strengthening method of crude drugs, composition containing crude drug strengthening antitumor activity, evaluating method of antitumor effectiveness by crude drug treatment, and evaluating method of antitumor effectiveness of crude drug | |
| DE69721759T2 (en) | TRANSDERMAL DEVICE | |
| WO2005027936A3 (en) | Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans | |
| WO2005077395A1 (en) | Physiologically active composition and process for producing the same | |
| JPH06312937A (en) | Production of substance having curing effect for wound | |
| JP2004344079A (en) | Chaaga-containing health auxiliary food | |
| CA2590549C (en) | Therapeutic agent for polycystic ovary syndrome (pcos) | |
| EP1576959B1 (en) | Softgel of nlkj (neutral lipids obtained from kernels of job's tears) for treating prostate diseases | |
| JP4896332B2 (en) | Bioactive composition based on the active ingredients of basidiomycetes and araceae | |
| CN104940934A (en) | Pharmaceutical composition used for promoting skin healing and application thereof | |
| EP1506012A1 (en) | Use of a vaccine for active immunization against cancer | |
| JP2003040795A (en) | Antihyperlipidaemic composition and method for manufacturing the same | |
| CN111617235A (en) | Application of IL-12 in postoperative antitumor aspect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070926 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080926 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080926 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090926 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100926 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100926 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110926 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110926 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120926 Year of fee payment: 15 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120926 Year of fee payment: 15 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130926 Year of fee payment: 16 |
|
| EXPY | Cancellation because of completion of term |